Evidence map›Paper›PMID 38467768›Full record

ArticleLeukemia2024

STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response.

Bhakti Patel, Yifan Zhou, Rachel L Babcock, Feiyang Ma, M Anna Zal, Dhiraj Kumar, Yusra B Medik, Laura M Kahn, Josué E Pineda, Elizabeth M Park and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Role of the STAT3 Signaling Pathway in Cell Proliferation and Inflammation in Psoriasis and Approaches for Targeted Therapies: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  3. Favorable response to second-line sirolimus regardless ofTherapeutic advances in hematology · 2026
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Bhakti PatelDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yifan ZhouDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rachel L BabcockDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Feiyang MaMolecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, USA.
M Anna ZalDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dhiraj KumarHerbert Irving Cancer Center and Department of Genetics and Development, Columbia University, New York, NY, USA.ORCID 0000-0002-6085-5911
Yusra B MedikDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Laura M KahnDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Josué E PinedaDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elizabeth M ParkDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sarah M SchneiderDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-7027-7978
Ximing TangDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maria Gabriela RasoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Collene R JeterDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tomasz ZalDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Karen Clise-DwyerDepartment of Stem Cell Transplantation and Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Khandan KeyomarsiDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Filippo G GiancottiHerbert Irving Cancer Center and Department of Genetics and Development, Columbia University, New York, NY, USA.ORCID 0000-0002-0541-9519
Simona CollaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-6583-8910
Stephanie S WatowichDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. swatowic@mdanderson.org.ORCID 0000-0003-1969-659X

Funding

TRANSLATIONAL AND ANALYTICAL CHEMISTRY COREP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PETER W PISTERS · 1985 to 2026
$279.3M
Mechanisms governing metastatic dormancy and reactivationR35CA197566 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GIANCOTTI, FILIPPO G · 2016 to 2022
$6.7M
Defining Protective Responses in Hematopoietic Cells Mediated by STAT3 Anti-Inflammatory ActivityR01AI133822 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WATOWICH, STEPHANIE S · 2018 to 2022
$2.1M
Super-Resolution OMX MicroscropeS10RR029552 · NCRR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ZAL, TOMASZ · 2011 to 2011
$1.0M
NovaSeq6000S10OD024977 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUFF, VICKI · 2018 to 2018
$995k
Regulation and function of nonlymphoid organ CD103+ dendritic cellsR56AI109294 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WATOWICH, STEPHANIE S · 2021 to 2021
$481k
The role of the gut microbiome in ICB-induced anti-tumor response and toxicityF32CA271513 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PARK, ELIZABETH M. · 2023 to 2023
$66k
NCI NIH HHS F32 CA271513NCI NIH HHS P30 CA016672NCI NIH HHS R35 CA197566NCRR NIH HHS S10 RR029552NIAID NIH HHS R01 AI133822NIAID NIH HHS R56 AI109294NIH HHS S10 OD024977
6 · The paper itself

Abstract

Hematopoietic stem and progenitor cells (HSPCs) maintain blood-forming and immune activity, yet intrinsic regulators of HSPCs remain elusive. STAT3 function in HSPCs has been difficult to dissect as Stat3-deficiency in the hematopoietic compartment induces systemic inflammation, which can impact HSPC activity. Here, we developed mixed bone marrow (BM) chimeric mice with inducible Stat3 deletion in 20% of the hematopoietic compartment to avoid systemic inflammation. Stat3-deficient HSPCs were significantly impaired in reconstitution ability following primary or secondary bone marrow transplantation, indicating hematopoietic stem cell (HSC) defects. Single-cell RNA sequencing of Lin

Indexed as

Autocrine CommunicationHematopoietic Stem CellsInterferon Type ISTAT3 Transcription FactorAnimalsMiceMice, Inbred C57BLMice, KnockoutSignal TransductionInterferon Type IStat3 protein, mouseSTAT3 Transcription Factor

Identifiers

PMID38467768
PMCPMC11283865

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.